Fellow

Niall Martin is Chief Executive Officer at Artios Parma Ltd. He is an industry pioneer and expert in drug discovery who has conducted and led ground-breaking translational work that has resulted in the development of novel medicines for the treatment of cancer patients. He co-invented the drug Lynparza which went on to become the world’s first marketed DNA-repair-enzyme inhibitor and has now been administered to more than 100,000 patients worldwide. He is an outstanding leader in the biotech space whose dedication and vision has been instrumental in the development of several precision DNA repair and DUB inhibitors, which are benefiting cancer patients around the world.